News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
New Clinical Data Move Cabaletta Closer to First Autoimmune CAR-T Approval
The company reported encouraging clinical data for its CAR T-cell therapy, RESE-CEL™.
Vivodyne and Opus Genetics Named Most Innovative Biotech Companies of 2026 by Fast Company
The companies are spun out of Penn Engineering and Penn Medicine, respectively.
GemmaBio Joins Lilly Gateway Labs as First Tenant
GemmaBio was co-founded by Penn Medicine Emeritus Professor James M. Wilson, MD, PhD.
Vetigenics Raises $10 Million for Pet Cancer Treatment Trials
The company will use the funds to further advance its lead cancer therapies for dogs and cats through pivotal clinical trials.
Agni Semiconductor Receives $5 Million Strategic Investment
Agni is developing a high speed, low power, multi-bit non-volatile memory based on Penn technology.
NextUP Program Provides Impact Grant Funding for Promising Pre-commercial Penn Ideas and Technologies
Applicants must include a Penn faculty member as a lead participant and an invention disclosure must be submitted to PCI.
Ascidian Therapeutics and Eli Lilly Establish Global Research Partnership
Ascidian was founded with technology developed by Jean Bennett, MD, PhD.
Exyn Technologies Completes a Successful IPO
Exyn raised $19.4 million in an initial public stock offering in May.
Meet the Penn I-Corps Spring 2026 Teams
The Spring 2026 teams have completed the Penn I-Corps program.
Craig Gravitz, JD, Joins PCI as Executive Director of PCI Ventures
Gravitz joins PCI from the Advanced Research Projects Agency for Health (ARPA‑H).